Cytosorbents (CTSO) to Release Earnings on Wednesday

Cytosorbents (NASDAQ:CTSO) is projected to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 14th. Analysts expect Cytosorbents to post earnings of ($0.08) per share and revenue of $9.01 million for the quarter.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. The business had revenue of $9.20 million for the quarter, compared to analysts’ expectations of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Performance

CTSO opened at $0.87 on Monday. The stock has a market cap of $54.53 million, a PE ratio of -2.42 and a beta of 1.17. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.61. The stock’s 50 day simple moving average is $1.02 and its 200-day simple moving average is $1.00.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CTSO. StockNews.com began coverage on Cytosorbents in a research report on Monday, May 5th. They set a “hold” rating on the stock. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Friday, May 2nd. Finally, HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Thursday, April 3rd. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Cytosorbents currently has an average rating of “Moderate Buy” and an average target price of $4.67.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.